← Back to Search

Immunomodulatory Agent

Venetoclax + Lenalidomide + Rituximab for Mantle Cell Lymphoma

Phase 1
Recruiting
Led By Tycel Phillips, M.D.
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Laboratory, radiographic, physical exam findings and/or symptoms attributable to MCL
ECOG Performance Status less or equal to 2
Must not have
Known history of CNS or leptomeningeal by MCL prior to study enrollment
Prior treatment for MCL with chemotherapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 4 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if an experimental drug called venetoclax, when combined with lenalidomide and rituximab, is safe and effective in treating people with Mantle Cell Lymphoma.

Who is the study for?
This trial is for adults over 18 with untreated Mantle Cell Lymphoma, who are in relatively good health (ECOG ≤2), not pregnant or breastfeeding, and can take oral medication. They must join the Revlimid REMS® program, agree to pregnancy testing if applicable, use contraception, and have no recent strong drug interactions or other cancers within 2 years.
What is being tested?
The study tests a combination of venetoclax with lenalidomide and rituximab for safety and effectiveness against MCL. Participants will receive this experimental treatment to see how well it works compared to current treatments.
What are the potential side effects?
Possible side effects include digestive issues, risk of infection due to lowered immune response, potential allergic reactions to drugs involved, fatigue from treatment regimen impact on body's normal function. Specific side effect profiles will be monitored closely.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My tests show I have mantle cell lymphoma.
Select...
I can take care of myself but might not be able to do heavy physical work.
Select...
I am 18 years old or older.
Select...
My diagnosis is mantle cell lymphoma confirmed by tissue examination.
Select...
I am registered and can follow the Revlimid REMS program requirements.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My cancer has spread to my brain or spinal cord.
Select...
I have received chemotherapy for mantle cell lymphoma.
Select...
I have taken a strong or moderate drug that affects liver enzymes within the last week.
Select...
I have a serious heart condition.
Select...
I do not have an active Hepatitis B or C infection.
Select...
I have moderate to severe numbness, tingling, or pain in my hands or feet.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
The proportion of patients that respond to treatment
The proportion of patients with a Complete Response (CR)

Side effects data

From 2022 Phase 3 trial • 389 Patients • NCT02005471
33%
Neutropenia
11%
SARS-CoV-2 test positive
11%
Sepsis
11%
Abdominal pain
11%
Pneumonia
11%
Rhinovirus infection
11%
COVID-19
11%
Gastroenteritis
11%
Pneumonia pseudomonal
11%
Electrocardiogram QT prolonged
11%
Anaemia
11%
Neutrophil count decreased
11%
Hypokalaemia
11%
Febrile neutropenia
11%
Supraventricular tachycardia
11%
Blood creatinine increased
11%
White blood cell count decreased
11%
Dermatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Bendamustine + Rituximab Crossover Substudy
Venetoclax + Rituximab Re-Treatment Substudy
Venetoclax + Rituximab Main Study
Bendamustine + Rituximab Main Study

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Venetoclax, Lenalidomide, RituximabExperimental Treatment3 Interventions
Rituximab 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12 Lenalidomide 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12. Venetoclax PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Venetoclax
2019
Completed Phase 3
~2200
Lenalidomide
2005
Completed Phase 3
~2240
Rituximab
1999
Completed Phase 4
~2990

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
602 Previous Clinical Trials
1,923,552 Total Patients Enrolled
University of Michigan Rogel Cancer CenterLead Sponsor
300 Previous Clinical Trials
24,337 Total Patients Enrolled
Tycel Phillips, M.D.Principal InvestigatorCity of Hope Medical Center
1 Previous Clinical Trials
15 Total Patients Enrolled

Media Library

Lenalidomide (Immunomodulatory Agent) Clinical Trial Eligibility Overview. Trial Name: NCT03523975 — Phase 1
Mantle Cell Lymphoma Research Study Groups: Venetoclax, Lenalidomide, Rituximab
Mantle Cell Lymphoma Clinical Trial 2023: Lenalidomide Highlights & Side Effects. Trial Name: NCT03523975 — Phase 1
Lenalidomide (Immunomodulatory Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03523975 — Phase 1
~9 spots leftby Jun 2027